Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus

Author(s)

Aldar, H. ^[1] ; Lapa, A. T. ; Bellini, B. ; Sinicato, N. A. ; Postal, M. ^[5] ; Fernandes, P. T. ; Costallat, L. T. L. ^[7] ; Marini, R. ^[8] ; Appenzeller, S. ^[9]

Affiliation

^[1] Univ Estadual Campinas. Dept Med

^[5] Univ Estadual Campinas. Dept Med

^[7] Univ Estadual Campinas. Dept Med

^[8] Univ Estadual Campinas. Dept Pediat

^[9] Univ Estadual Campinas. Dept Med

• Document type: Journal article
• Source: Lupus; v. 21, n. 11, p. 1225-1231, OCT 2012.
• Web of Science Citations: 4

Abstract

Objective: To investigate the prevalence of the anti-ribosomal P (anti-P) antibodies in childhood-onset systemic lupus erythematosus patients (cSLE), healthy controls and first degree relatives. To elucidate the association between anti-P and disease activity, laboratory and treatment features in cSLE patients. Methods: We included consecutive SLE patients with disease onset before 16 years. Controls were age- and sex-matched. SLE patients were assessed for clinical and laboratory SLE manifestations, disease activity (SLE Disease Activity Index (SLEDAI)), damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)) and current drug exposures. Mood disorders were determined through Becks Depression and Becks Anxiety Inventory. Anti-P measured by enzyme-linked immunosorbent assay. Results: We included 50 consecutive cSLE patients (mean age of 16.82 +/- 3.46 years), 35 first degree relatives (mean age of 38.73 +/- 3.89 years) and 20 health control (mean age of 18.3 +/- 4.97 years). Anti-P was observed in 13 (26%) cSLE patients and in no first-degree relative (p < 0.01) or control (p < 0.01). Anti-P was more frequently observed in patients with anxiety (p < 0.002). No other clinical, laboratory or treatment features, including SLEDAI and SDI scores were associated with the presence of anti-P in cSLE patients. Conclusion: Anti-P is frequently observed in cSLE patients and was associated with the presence of anxiety in this cohort of cSLE. Lupus (2012) 21, 1225-1231. (AU)

• FAPESP's process: 09/06049-6 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in Systemic lupus erythematosus
• Grantee: Simone Appenzeller
• Support Opportunities: Scholarships in Brazil - Young Researchers
• FAPESP's process: 08/02917-0 - Blood and cerebrospinal fluid biomarkers associated with structural and functional central nervous system abnormalities in systemic lupus erythematosus
• Grantee: Simone Appenzeller
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 09/13046-3 - Analysis of the prevalence of anti-P, anti-NR2 antibodies and the neuronal marker S100 beta in sistemic lupus erythematosus.
• Grantee: Henrique Aldar
• Support Opportunities: Scholarships in Brazil - Master